Is Somatropin legal?
FDA approved- FDA status
- Somatropin is FDA approved for: Paediatric growth hormone deficiency; Adult growth hormone deficiency; Turner syndrome; Prader-Willi syndrome; Growth failure associated with chronic kidney disease; Children born small for gestational age without catch-up growth; Idiopathic short stature; SHOX deficiency; Noonan syndrome; HIV-associated wasting or cachexia (Serostim); Short bowel syndrome (Zorbtive, no longer marketed).
- Compounding
- It is a prescription medicine. Use outside the approved indication is off-label and a clinician’s decision. Compounded copies are restricted when the approved product is available.
- Prescription
- A licensed US clinician can prescribe Somatropin.
- Sport
- Prohibited in sport under the World Anti-Doping Agency list.
US status checked October 2026 against FDA’s compounding lists. Sources at the foot of the page.
What is somatropin?
Somatropin is recombinant human growth hormone (rhGH), a lab-made copy of the 191-amino-acid hormone released by the pituitary gland. Its sequence is identical to the main 22-kilodalton form of natural growth hormone1. It is the benchmark against which growth hormone secretagogues such as sermorelin, ipamorelin and CJC-1295 are measured.
Growth hormone was first used medically as an extract from human pituitary glands collected after death. That supply was stopped in 1985 after cases of Creutzfeldt-Jakob disease were linked to it, and recombinant growth hormone made by genetically engineered cells replaced it the same year. Somatropin is now sold under many brand names, including Genotropin, Humatrope, Norditropin, Nutropin, Omnitrope, Saizen and Zomacton, plus Serostim for HIV-associated wasting.
Approved uses include growth hormone deficiency in children and adults, Turner syndrome, Prader-Willi syndrome, HIV-associated wasting and short bowel syndrome, along with several other childhood growth disorders. It is also one of the most widely misused performance and anti-aging drugs.
- Anecdotal only
- In vitro only
- Animal models only
- Preliminary human
- Clinical trials
- Regulator approved
How somatropin works
Growth hormone tells the liver and other tissues to make IGF-1, a growth factor that drives bone growth in children and helps maintain muscle, bone and metabolism in adults. Growth hormone also acts directly on fat cells, releasing stored fat, and it raises blood sugar by making the body less responsive to insulin. Secretagogues ask the pituitary to release more of its own growth hormone. Somatropin skips that step and delivers the hormone itself, so the dose is more predictable but the body's own brakes no longer limit the level.
In precise terms, somatropin binds the growth hormone receptor, a cytokine-family receptor that signals mainly through JAK2 and STAT5, and induces hepatic and local production of insulin-like growth factor I (IGF-I), the main mediator of its growth effects1. Direct effects include increased lipolysis, nitrogen retention and protein synthesis, and reduced insulin sensitivity. In growth hormone-deficient adults, replacement increases lean body mass, decreases fat mass, and improves VO2max and maximal power output1. Exogenous somatropin suppresses the body's own growth hormone release through negative feedback. Natural growth hormone circulates as a mix of isoforms, while rhGH is only the 22 kDa form, a difference that underpins doping tests1.
IGF-1 analogues act at the end of the axis, directly on tissues, bypassing the pituitary and the liver.
What the research shows on somatropin
Somatropin has decades of clinical data in approved conditions. In children with growth hormone deficiency, daily injections reliably increase growth rate, and more than 30 years of use have built a long safety record, though debate continues about final-height gains in some conditions and about risk and benefit given the cost4. In Turner syndrome, where untreated girls end up about 20 cm shorter than average, routine rhGH treatment improves adult height7. In HIV-associated wasting, a large randomized trial of Serostim found that 12 weeks of treatment increased lean body mass, body weight and work output compared with placebo8.
Newer research has focused on reducing the burden of daily injections. Two phase 3 trials in children with growth hormone deficiency compared weekly long-acting versions with daily somatropin. Weekly somatrogon was non-inferior, with similar growth rates and safety2, and weekly lonapegsomatropin produced a slightly higher growth rate than daily somatropin over 52 weeks6. A meta-analysis of eight trials in boys found that adding aromatase inhibitors to rhGH increased growth velocity and predicted adult height, though this remains an off-label strategy5.
For healthy adults and athletes, evidence is much weaker. Controlled studies of growth hormone in healthy, trained people are scarce, and results from deficient patients cannot be extrapolated to them1. An earlier review noted there was no controlled study showing a profound effect of hGH on workload capacity in healthy adults3. Trials in healthy older adults have shown some gain in lean mass and loss of fat but not consistent gains in strength or function, alongside frequent side effects.
Studied for: Growth hormone deficiency, Short stature syndromes, HIV wasting, Short bowel syndrome.
Somatropin reference data
| Molecular weight | 22,124 Da |
|---|---|
| CAS number | 12629-01-5 |
| FDA status | Paediatric growth hormone deficiency; Adult growth hormone deficiency; Turner syndrome; Prader-Willi syndrome; Growth failure associated with chronic kidney disease; Children born small for gestational age without catch-up growth; Idiopathic short stature; SHOX deficiency; Noonan syndrome; HIV-associated wasting or cachexia (Serostim); Short bowel syndrome (Zorbtive, no longer marketed) |
| Prohibited in sport | Yes, under the WADA prohibited list |
Somatropin dosage in published research
Once daily, indication-dependent. A reference pattern, not a prescription.
How somatropin is used in practice
In approved use, somatropin is prescribed by endocrinologists after formal testing, usually as daily subcutaneous injections from a pen, with doses adjusted by weight, age, sex and IGF-1 levels. Weekly long-acting products are now also available for some patients. Treatment is expensive and usually requires insurer prior authorization.
Outside approved use, growth hormone is distributed for anti-aging, bodybuilding and athletic performance. In the US, distributing growth hormone for uses other than approved indications is a specific federal crime, which is one reason many wellness and telehealth clinics offer secretagogues instead. Black-market and research-chemical growth hormone, often imported, may be counterfeit, under-dosed or contaminated. Growth hormone is prohibited in sport, and detection methods compare natural and recombinant isoforms or measure markers such as IGF-I1.
Somatropin risks and side effects
Common side effects in adults are fluid retention and swelling, joint and muscle pain, and carpal tunnel symptoms, all linked to dose. Somatropin reduces insulin sensitivity and can raise blood sugar, so people with diabetes may need medication changes. In children, recognized risks include raised pressure in the skull, slipped capital femoral epiphysis at the hip and worsening scoliosis.
It should not be used in active cancer, in acute critical illness (where growth hormone increased deaths in intensive care trials), in proliferative diabetic retinopathy, or for growth in children whose growth plates have closed. Glucocorticoids blunt its effects, and it can alter the metabolism of drugs cleared by liver enzymes. Long-term safety questions remain under study for some patient groups4.
Supraphysiologic use for performance or anti-aging raises additional concerns: diabetes, high blood pressure, enlarged organs and acromegaly-like features. Unregulated products add infection and dosing risks.
Reported side effects
Alternatives to somatropin
For confirmed deficiency, long-acting growth hormones such as somapacitan, somatrogon and lonapegsomatropin are approved alternatives with weekly dosing. Mecasermin, recombinant IGF-1, is used for severe primary IGF-1 deficiency. Tesamorelin (Egrifta) is approved for excess abdominal fat in HIV-associated lipodystrophy.
For anti-aging, body composition or recovery, there is no approved growth hormone indication. Resistance training, adequate protein and sleep, weight loss and treatment of low testosterone or thyroid disease where present have better risk-benefit profiles. Secretagogues are sometimes offered as a gentler option, but they lack strong outcome data too.
The bottom line on somatropin
Somatropin is an established, effective treatment for growth hormone deficiency and several specific conditions. In healthy adults, the benefits are modest, the side effects are real, and use outside approved indications is illegal in the US. It belongs under endocrinologist care, not in a performance stack.
Questions for a clinician
- What evidence applies to my situation, and at what level?
- What established alternatives should I consider first?
- What monitoring would be necessary, and how often?
Somatropin FAQ
What is Somatropin?
Recombinant human growth hormone itself, the reference compound every secretagogue on this site is compared against. It is classed as IGF & growth factors.
Is Somatropin FDA approved?
Yes. Somatropin is FDA approved for: Paediatric growth hormone deficiency; Adult growth hormone deficiency; Turner syndrome; Prader-Willi syndrome; Growth failure associated with chronic kidney disease; Children born small for gestational age without catch-up growth; Idiopathic short stature; SHOX deficiency; Noonan syndrome; HIV-associated wasting or cachexia (Serostim); Short bowel syndrome (Zorbtive, no longer marketed).
Is Somatropin legal in the US?
Somatropin is FDA approved for: Paediatric growth hormone deficiency; Adult growth hormone deficiency; Turner syndrome; Prader-Willi syndrome; Growth failure associated with chronic kidney disease; Children born small for gestational age without catch-up growth; Idiopathic short stature; SHOX deficiency; Noonan syndrome; HIV-associated wasting or cachexia (Serostim); Short bowel syndrome (Zorbtive, no longer marketed). It is a prescription medicine. Use outside the approved indication is off-label and a clinician’s decision. Compounded copies are restricted when the approved product is available.
What dose of Somatropin is used in research?
Published research and practitioner protocols report 200 mcg - 1 mg, once daily, indication-dependent. This is a reference range, not a recommendation; dosing should be set by a licensed clinician.
What are the side effects of Somatropin?
Reported side effects include peripheral oedema, arthralgia, carpal tunnel syndrome, insulin resistance, myalgia. Contraindications: active malignancy, acute critical illness, proliferative diabetic retinopathy, closed epiphyses for growth indications.
What is the half-life of Somatropin?
The reported half-life of Somatropin is ~3-5 hours (subcutaneous).
Is Somatropin banned in sport?
Yes. Somatropin falls under the World Anti-Doping Agency prohibited list.
References
Regulatory and primary sources
- FDA: Bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) ↗ · content current as of April 22, 2026; checked October 18, 2026
- FDA: Bulk drug substances used in compounding under section 503A ↗ · how the 503A categories work
- PubChem compound record (CID 137552069) ↗ · structure, identifiers, synonyms
- DailyMed: FDA-approved labeling for Somatropin ↗ · indications, dosing, warnings as approved
- FDA Drugs@FDA database ↗ · approval history
- WADA Prohibited List ↗ · current year
- CAS Registry Number 12629-01-5 ↗ · chemical identity
Published literature
- Growth hormone.Handb Exp Pharmacol 2010.PubMed 20020365 · doi:10.1007/978-3-540-79088-4_8
- Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study.J Clin Endocrinol Metab 2022.PubMed 35405011 · doi:10.1210/clinem/dgac220
- Doping with growth hormone.J Pediatr Endocrinol Metab 2001.PubMed 11592563 · doi:10.1515/jpem-2001-0802
- GH and IGF-1 Replacement in Children.Handb Exp Pharmacol 2020.PubMed 31932988 · doi:10.1007/164_2019_337
- Aromatase inhibitors for short stature in male children and adolescents treated with growth hormone: a meta-analysis of randomized controlled trials.BMC Pediatr 2024.PubMed 39696162 · doi:10.1186/s12887-024-05301-0
- Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial.J Clin Endocrinol Metab 2021.PubMed 34272849 · doi:10.1210/clinem/dgab529
- Growth Hormone Therapy for Turner Syndrome.Pediatr Endocrinol Rev 2018.PubMed 30378785 · doi:10.17458/per.vol16.2018.bnb.ghtherapyturnersyndrome
- Mammalian cell-derived somatropin : a review of its use in the management of HIV-associated wasting.Drugs 2006.PubMed 16526830 · doi:10.2165/00003495-200666030-00014
Literature retrieved from PubMed on October 16, 2026, favouring human studies and reviews. Numbered markers in the text show which paper supports which statement; uncited entries are background reading.